A predictive serum miRNA signature impacts diffuse large B‐cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis - Regazzo, Giulia; Vari, Giulia; Marchesi, Francesco; Díaz Méndez, Ana Belén; Di Giuliani, Marta; Sacconi, Andrea; Palombi, Francesca; Lulli, Valentina; Goeman, Frauke; Novello, Mariangela; Tomassi, Martina; Papa, Elena; et al. (British journal of haematology, 2025)
Keywords: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers; Biomarkers, Tumor - blood; Cell Line, Tumor; Cell proliferation; Cell Survival - genetics; Cell viability; circulating microRNAs; Cyclophosphamide - therapeutic use; diffuse large B‐cell lymphoma; Doxorubicin - therapeutic use; Female; Ferroptosis; Ferroptosis - genetics; ferroptosis regulators; Gene Expression Regulation, Neoplastic; Germinal centers; Homeostasis; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse - blood; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Large B-Cell, Diffuse - pathology; Male; Medical prognosis; MicroRNAs; MicroRNAs - blood; MicroRNAs - genetics; Middle Aged; miRNA; Neoplasm Proteins; predictive biomarkers; Prednisone - therapeutic use; Prognosis; Rituximab; RNA, Neoplasm - blood; Therapeutic applications; Thioredoxin Reductase 1 - antagonists & inhibitors; Thioredoxin Reductase 1 - genetics; Thioredoxin Reductase 1 - metabolism; Vincristine - therapeutic use; ferroptosis regulators; predictive biomarkers; circulating microRNAs; diffuse large B‐cell lymphoma